Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser showdown: which glaucoma protocol wins?

NCT ID NCT03798223

Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study compares different ways of performing a laser treatment called selective laser trabeculoplasty (SLT) for people with open-angle glaucoma or high eye pressure. 400 participants will receive SLT using one of several protocols, and researchers will track how much their eye pressure drops over three years. The goal is to find the safest and most effective approach to lower eye pressure and possibly delay the need for eye drops or surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Selective laser trabeculoplasty (SLT) with pilocarpine and tetracaine eye drops
What this could lead to
If successful, this could establish a standard, more effective laser procedure to lower eye pressure and reduce the need for daily eye drops in glaucoma patients.
What could go wrong
This is a mid-stage trial comparing different laser techniques, not testing a new drug. The results may show only modest differences between protocols, and long-term effectiveness varies by patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

400 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis primary open-angle glaucoma, pseudo-exfoliative glaucoma or ocular hypertension. * intra-ocular pressure (IOP) at least 18 mmHg treatment day. * treatment is performed by an experienced laser surgeon. * SLT treatment and follow-up are expected to be possible to perform in an adequate way, considering anatomical factors, age and the general health of the patient. Exclusion Criteria: * change of IOP-lowering medication during the last three months. * planned change of intra-ocular-pressure-lowering medication. * previous glaucoma surgery (other than SLT and ALT) * previous intra-ocular surgery during the last three months. * previous intra-ocular inflammatory disease during the last year. * planned intra-ocular surgery. * hyper-pigmented anterior chamber angle.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma, open-angle are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma, open-angle Ocular hypertension Pseudoexfoliation glaucoma

Contacts and locations

Locations

  • Ogonkliniken NU-sjukvarden

    Uddevalla, Västra Götaland County, 45153, Sweden

  • Ogonkliniken, Sahlgrenska Universitetssjukhuset

    Mölndal, Västra Götaland County, 43130, Sweden

  • Ogonkliniken, Skaraborgs Sjukhus

    Skövde, Västra Götaland County, 54142, Sweden

  • Ogonkliniken, Sodra Alvsborgs Sjukhus

    Borås, Västra Götaland County, 50182, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.